Mk-2461

Mk-2461

SCHEMBL2326906

CN(CC1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MET

The experimentally established mechanism targets of Mk-2461. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET known ✓ P08581 20/20 1.00
▸ MST1R Q04912 2/20 1.00
▸ AURKA O14965 1/20 1.00
▸ JAK2 O60674 1/20 1.00
▸ ABL1 P00519 1/20 1.00
▸ NTRK1 P04629 1/20 1.00
▸ RET P07949 1/20 1.00
▸ CYP3A4 P08684 1/20 1.00
▸ PDGFRB P09619 1/20 1.00
▸ FGFR1 P11362 1/20 1.00
▸ CYP2C9 P11712 1/20 1.00
▸ NQO2 P16083 1/20 1.00
▸ FLT1 P17948 1/20 1.00
▸ FGFR2 P21802 1/20 1.00
▸ FGFR3 P22607 1/20 1.00
▸ FECH P22830 1/20 1.00
▸ FLT4 P35916 1/20 1.00
▸ KDR P35968 1/20 1.00
▸ FLT3 P36888 1/20 1.00
▸ MAPK9 P45984 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mk-2461 SCHEMBL29394185 1.00 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL29356324 1.00 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL29529144 1.00 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL2326614 1.00 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL93526 1.00 MET (1.00) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1269865 0.99 MET (0.98) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1270766 0.99 MET (0.98) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1269863 0.99 MET (0.98) METMST1RAURKAJAK2ABL1
Mk-2461 SCHEMBL1270764 0.99 MET (0.98) METMST1RAURKAJAK2ABL1
SCHEMBL4316174 0.92 MET (0.84) METMST1RAURKAJAK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896421-B1 BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET MERCK SHARP & DOHME (US) 2011-09-14 — — EP claimed
EP-1896422-B1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME (US) 2011-08-17 — — EP claimed
US-20090197908-A1 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met MERCK SHARP & DOHME LLC 2009-08-06 — — US claimed
US-7550478-B2 Tyrosine kinase inhibitors MERCK & CO. INC. (US) 2009-06-23 — — US claimed
EP-1896422-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-03-12 — — EP claimed
WO-2007002258-A2 BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET MERCK & CO., INC. (US) 2007-01-04 — — WO claimed
US-20060293358-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2006-12-28 — — US claimed
US-20160058751-A1 COMPOSITION AND METHOD FOR TREATING CANCER CELLWORKS GROUP, INC. (US) 2016-03-03 — — US disclosed
US-8207186-B2 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET MERCK SHARP & DOHME CORP. (US) 2012-06-26 — — US disclosed
US-8207186-B2 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET MERCK SHARP & DOHME CORP. (US) 2012-06-26 — — US disclosed
US-8207186-B2 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET MERCK SHARP & DOHME CORP. (US) 2012-06-26 — — US disclosed
EP-1896421-B1 BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET MERCK SHARP & DOHME (US) 2011-09-14 — — EP disclosed
EP-1896422-B1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME (US) 2011-08-17 — — EP disclosed
US-7550478-B2 Tyrosine kinase inhibitors MERCK & CO. INC. (US) 2009-06-23 — — US disclosed
US-7550478-B2 Tyrosine kinase inhibitors MERCK & CO. INC. (US) 2009-06-23 — — US disclosed
US-7550478-B2 Tyrosine kinase inhibitors MERCK & CO. INC. (US) 2009-06-23 — — US disclosed
EP-1896422-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-03-12 — — EP disclosed
WO-2007002258-A2 BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET MERCK & CO., INC. (US) 2007-01-04 — — WO disclosed
WO-2007002258-A2 BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET MERCK & CO., INC. (US) 2007-01-04 — — WO disclosed
US-20060293358-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2006-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160058751-A1 COMPOSITION AND METHOD FOR TREATING CANCER KRAS, NRAS, TP53 MET 271/4885MST1R 4041/4885AURKA 510/4885
US-20060293358-A1 Tyrosine kinase inhibitors ABL1, ERBB2, RET MET 4/4885MST1R 163/4885AURKA 464/4885
US-20090197908-A1 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met MET, RET, ERBB2 MET 1/4885MST1R 62/4885AURKA 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback